Analyst Ratings January 28, 2026

Goldman Sachs Sticks With Buy on Lam Research, Sets $180 Target After Strong Quarter

Lam Research beats revenue and margin estimates; guidance and analyst upgrades underscore sector momentum

By Caleb Monroe LRCX
Goldman Sachs Sticks With Buy on Lam Research, Sets $180 Target After Strong Quarter
LRCX

Goldman Sachs has reiterated its Buy rating on Lam Research and set a $180 price target after the semiconductor equipment maker posted quarterly results that surpassed consensus on both revenue and gross margin. Management offered first-quarter guidance above Street expectations, and several other brokerages have raised targets, citing robust system sales and memory upgrade activity.

Key Points

  • Goldman Sachs reaffirmed a Buy rating on Lam Research with a $180 price target after quarterly results beat revenue and margin expectations - impacts the semiconductor equipment sector and hardware supply chains.
  • Lam Research reported $5.35 billion in revenue, a 49.7% gross margin, $3.36 billion in Systems revenue and $1.98 billion in Service revenue; management guided Q1 revenue at a $5.70 billion midpoint and operating margin to 34.0% - relevant to investors tracking wafer fabrication equipment demand and corporate margins.
  • Multiple brokerages raised price targets or ratings, reflecting strong system sales and memory upgrade dynamics; these analyst moves influence market sentiment in semiconductors and technology equipment stocks.

Goldman Sachs has reaffirmed a Buy rating on Lam Research (NASDAQ:LRCX) and assigned a $180.00 price target following a quarter that outperformed market expectations. The firm cited the company’s quarterly results and outlook as drivers for the call, which comes as Lam Research shares have exhibited strong momentum - InvestingPro data indicate a 224% price return over the past year and show the stock trading near its 52-week high of $243.99.

On the top line, Lam Research reported revenue of $5.35 billion, modestly above the Street consensus of $5.25 billion. The company delivered a gross margin of 49.7%, beating Goldman Sachs’ expectation of 48.7% and the Street estimate of 48.6%. Within revenue mixes, Systems sales totaled $3.36 billion and Service revenue was $1.98 billion, with the latter figure significantly outstripping analyst projections.

Lam’s latest performance aligns with its recent trailing metrics. According to InvestingPro, the company recorded a 49.3% gross profit margin over the last twelve months and achieved year-over-year revenue growth of 25.7%.

Management issued first-quarter guidance that also eclipsed consensus. At the midpoint, revenue is projected at $5.70 billion versus the Street’s $5.37 billion forecast. The company guided operating margin to 34.0%, which surpasses analyst estimates, and provided non-GAAP earnings-per-share guidance of $1.25 to $1.45.


Analyst framing and valuation

Goldman Sachs highlighted several areas it expects market participants to focus on going forward, including the outlook for wafer fabrication equipment in 2026, the trajectory of the NAND upgrade cycle, order trends in China, and the path for gross margins. The $180 price target published by Goldman reflects a 31X price-to-earnings multiple applied to its normalized EPS estimate of $5.80.


Downside considerations and company financials

The firm noted specific downside risks, among them the possibility of pauses in NAND supplier upgrade spending, the imposition of further U.S. government export restrictions, and industry shifts toward greater lithography intensity at the expense of deposition and etch applications. Despite these risk factors, Lam Research reported a solid liquidity position, with a current ratio of 2.21, and has increased its dividend for 12 consecutive years, as noted in InvestingPro Tips.


Peer analyst activity

Lam Research has attracted upward revisions from multiple brokerages since the reported quarter. Wells Fargo upgraded the stock from Equal Weight to Overweight and raised its price target to $250.00, citing supportive memory supply and demand dynamics. Stifel lifted its price target to $250.00 from $160.00 while maintaining a Buy rating, pointing to strong systems sales growth in 2025 that outpaced the broader wafer fabrication equipment market. RBC Capital initiated coverage with an Outperform rating and a $260.00 price target, attributing its view to NAND upgrade drivers and foundry share gains. Morgan Stanley raised its price target to $211.00 and kept an Equalweight rating based on expectations of continued outperformance in coming years.


Sector context

Activity in the broader semiconductor space also remains notable. The article’s coverage includes SK Hynix’s announcement of a $13 billion investment in a new HBM packaging plant in Korea, scheduled for completion by late 2027, a development that reflects continued capital deployment across memory and packaging segments.

Investors and market watchers will likely monitor Lam Research’s order trends, margin trajectory, and the pace of memory-related upgrades as they assess the sustainability of recent results and the assumptions underlying analyst valuations.

Risks

  • Potential pauses in NAND supplier upgrade spending could reduce demand for Lam Research’s systems and services, affecting the wafer fabrication equipment market.
  • Additional U.S. government export restrictions may constrain sales or order flows, with implications for global semiconductor supply chains and equipment vendors.
  • An industry shift toward greater lithography intensity versus deposition and etch applications could alter addressable demand for Lam Research’s core products.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026